GLEN ALLEN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the progression to the second cohort in the pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in he ...

GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of previously disclosed results from its Phase 3 ONWARD study in a peer-reviewed article in the European Journal of Internal Medicine entitled, "Low-dose ondansetron: A candidate prospective precision medicine to treat al ...

GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of previously disclosed results from its Phase 3 ONWARD study in a peer-reviewed article in the European Journal of Internal Medicine entitled, “Low-dose ondansetron: A candidate prospective precision medicine to treat a ...

文章核心观点 - 投资低价股票(低于2美元)存在巨大风险,但也可能带来高回报,需要结合风险和运气[1][2] - 文章介绍了7只可能在2025年前实现10倍增长的低价股票[1] 公司和行业总结 Reliance Global (RELI) - 公司是一家收购和管理美国零售保险代理的企业集团[3] - 公司最近宣布收购Spetner Associates,预计将使公司年收入增加一倍至2800万美元[5][6] - 公司股价在过去12个月内下跌了约95%,目前每股仅0.25美元,存在较大风险[4] aTyr Pharma (LIFE) - 公司专注于治疗导致肺部纤维化的肺部疾病[8] - 公司的主要候选药物Efzofitimod获得FDA和欧盟孤儿药资格认定,有望加快开发进度[9] - 公司还与日本杏林制药公司签订了价值高达1.75亿美元的合作协议[10] - 公司最近还宣布了员工股票期权计划,表明公司股价存在上涨空间[11] BioLineRx (BLRX) - 公司正在商业化治疗多发性骨髓瘤和其他罕见疾病的疗法[12] - 公司的多发性骨髓瘤治疗药物Aphexda在上市后第一个完整季度表现良好,渗透率不断提高[13][14] - 公司还在进行其他疾病的临床试验,整体发展势头良好[15] Knightscope (KSCP) - 公司生产全自主安保机器人,产品外观有些像未来主义电影中的场景[16][17] - 公司2023年收入同比增长128%至1280万美元,亏损也有所收窄[18][19] - 公司已在美国部署了1万台机器,并计划今年将员工成本降低30%[19] Adial Pharmaceuticals (ADIL) - 公司正在研发治疗酒精成瘾、阿片类药物成瘾等的候选药物AD04[20][21] - 公司已获得相关基因序列的专利权,目标市场规模可达400亿美元[21][22] - 但公司目前的现金流只能维持到2025年第一季度[23] Society Pass (SOPA) - 公司正在东南亚建立涵盖电商和金融科技的生态系统[25] - 公司最近一季度收入增长11%,现金充裕且无债务[26][27] - 公司获得了4000万美元的信用额度,显示机构投资者看好其发展前景[27] Enviva (EVA) - 公司生产可再生木质颗粒,作为化石燃料的低碳替代品[28] - 公司正在进行业务转型,最近一季度收入下降1.3%,亏损大幅增加[29][30] - 公司最近几个月未发布财报,存在破产重组的风险[31]

Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va., June 05, 2024 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the first patient has been dosed in a pharmacokineti ...

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m. ...

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m ...

GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We are making steady progress as it relates to AD04. We have initiated new a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38323 ADIAL PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3074668 State ...

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial's intellectual property protection and covers the combination of the Company's proprietary genetic diagno ...